Key facts
- It has raised $55.3M; the latest was Later Stage VC in Jun 2025.
- Notable investors include CDIB Capital Group, Mega International Commercial Bank, Alzheimer's Association, Axil Capital Partners, DCI Partners — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Elixiron
- ·The full record, as it builds
Funding rounds
No funding rounds for Elixiron are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elixiron
Developer of immuno-therapeutics intended to aid patients designed for neurodegenerative diseases, Hepatitis B, and cancer. The company's drugs target specific immuno-suppressive pathways including graft-versus-host disease and macrophage activation syndrome, enabling patients to potentially harness the full power of the immune system to fight cancer.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2017
- Employees
- 25
- Website
- elixiron.com/
- Ownership
- Privately Held (backing)
Elixiron doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elixiron shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elixiron in its N-PORT filings yet. We sweep new filings monthly.